Literature DB >> 23975361

Cross-cultural adaptation and validation of the Brazilian version of the Scleroderma Health Assessment Questionnaire (SHAQ).

Luiza F Rocha1, Roberta G Marangoni, Percival D Sampaio-Barros, Mauricio Levy-Neto, Natalino H Yoshinari, Eloisa Bonfa, Virginia Steen, Sergio C Kowalski.   

Abstract

The Scleroderma Health Assessment Questionnaire (SHAQ) is a feasible multisystem specific tool that has been extensively used as an additional assessment for systemic sclerosis (SSc). The aim of this study is to cross-culturally adapt and validate the Brazilian version of the SHAQ. Construct validity was assessed based on the correlations between SHAQ and both the Medical Outcomes Survey Short Form 36 version 2 (SF-36v2™) and the Health Assessment Questionnaire Disability Index (HAQ-DI). The correlation between the SHAQ and disease severity was assessed by Spearman's correlation coefficient. The reproducibility of the SHAQ was evaluated by the intraclass correlation coefficient (ICC). Among the 151 consecutive outpatients evaluated, 59 % had limited SSc subtype. The overall disease severity visual analog scale (VAS) of the SHAQ was statistically significantly correlated to HAQ-DI, pain VAS, and the SF-36v2™ physical component summary score (r = 0.595, r = 0.612, and r = -0.582, respectively; p < 0.001). Further analysis of all SF-36v2™ components revealed statistically significant correlations between overall disease severity VAS and bodily pain (r = -0.621, p < 0.001), vitality (r = -0.544, p < 0.001), physical function (r = -0.510, p < 0.001), and role limitation-physical dimensions (r = -0.505, p < 0.001). Moreover, digestive, pulmonary, and overall disease severity VASs were statistically significantly correlated to the number of organs involved (r = 0.178, p = 0.029; r = 0.214, p = 0.008; r = 0.282, p < 0.001). We also demonstrated high reproducibility for SHAQ (ICC = 0.757, 95 % confidence interval = 0.636-0.842). The Brazilian version of the SHAQ demonstrated both construct and discriminant validities as well as good reproducibility.

Entities:  

Mesh:

Year:  2013        PMID: 23975361     DOI: 10.1007/s10067-013-2370-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  32 in total

Review 1.  Targeted therapy for systemic sclerosis: how close are we?

Authors:  Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-Almirall
Journal:  Nat Rev Rheumatol       Date:  2010-04-13       Impact factor: 20.543

2.  Quality criteria were proposed for measurement properties of health status questionnaires.

Authors:  Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2006-08-24       Impact factor: 6.437

3.  The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.

Authors:  J F Fries; P W Spitz; D Y Young
Journal:  J Rheumatol       Date:  1982 Sep-Oct       Impact factor: 4.666

4.  Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.

Authors:  Diane Wild; Alyson Grove; Mona Martin; Sonya Eremenco; Sandra McElroy; Aneesa Verjee-Lorenz; Pennifer Erikson
Journal:  Value Health       Date:  2005 Mar-Apr       Impact factor: 5.725

5.  Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument.

Authors:  A Silman; A Akesson; J Newman; H Henriksson; G Sandquist; M Nihill; S Palfrey; R Lomas; F Wollheim; C Black
Journal:  J Rheumatol       Date:  1998-01       Impact factor: 4.666

6.  A cross-sectional comparison of three self-reported functional indices in scleroderma.

Authors:  A E Smyth; A J MacGregor; D Mukerjee; G M Brough; C M Black; C P Denton
Journal:  Rheumatology (Oxford)       Date:  2003-04-16       Impact factor: 7.580

7.  Clinical correlates of self-reported physical health status in systemic sclerosis.

Authors:  Marie Hudson; Russell Steele; Ying Lu; Brett D Thombs; Pantelis Panopalis; Murray Baron
Journal:  J Rheumatol       Date:  2009-05-15       Impact factor: 4.666

8.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  1997-11

9.  Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.

Authors:  Dinesh Khanna; Xiaohong Yan; Donald P Tashkin; Daniel E Furst; Robert Elashoff; Michael D Roth; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Philip J Clements
Journal:  Arthritis Rheum       Date:  2007-05

10.  Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument.

Authors:  Dinesh Khanna; Ron D Hays; Grace S Park; Yolanda Braun-Moscovici; Maureen D Mayes; Terry A McNearney; Vivien Hsu; Philip J Clements; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2007-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.